Cadonilimab plus standard care to preserve organ function in urinary cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new immunotherapy drug (cadonilimab) combined with standard care to see if it can help preserve your bladder or kidney function while treating high-risk urinary tract cancers. It's for people who need surgery but want to keep as much organ function as possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have either urothelial cancer (bladder, ureter, kidney lining) or kidney cancer (renal cell carcinoma) that has not spread to other organs and is considered high-risk.
- You have not had any previous systemic cancer treatment (like chemotherapy or immunotherapy) for this cancer.
- You are able to have surgery but are at risk of losing some organ function, or you have a strong wish to keep your organ working as much as possible.
- Your overall health is good: you can take care of yourself, your heart and lungs are working well, and you do not have active infections or uncontrolled conditions like high blood pressure or diabetes.
- You do not have active hepatitis B, hepatitis C, or HIV, and you have not had another cancer within the last 5 years (except certain treated skin or cervix cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemoradiation for cervical cancer that has spread to a few other places in the body. It aims to see if this combination can help control the cancer better.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
This trial tests two new drugs, vorolanib and cadonilimab, for people with advanced kidney cancer that hasn't been treated before. The combination aims to shrink tumors and slow down the cancer's growth.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) to treat HER2-positive high-risk upper tract urothelial cancer, aiming to save the kidney instead of removing it. The drugs target cancer cells and boost the immune system to fight the cancer.
Hear when a new Urinary System Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.